DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Aflibercept

Aflibercept

  • Phase I/II Study Evaluating the Safety and Clinical Efficacy of Temsirolimus and Bevacizumab in Patients with Chemotherapy Refra

    Phase I/II Study Evaluating the Safety and Clinical Efficacy of Temsirolimus and Bevacizumab in Patients with Chemotherapy Refra

  • Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities

    Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities

  • Recommendations from York and Scarborough Medicines

    Recommendations from York and Scarborough Medicines

  • COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION

    COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION

  • Value Assessment and Market Access of Innovative Biologics in China

    Value Assessment and Market Access of Innovative Biologics in China

  • Treat-And-Extend Therapy Using Aflibercept for Neovascular Age

    Treat-And-Extend Therapy Using Aflibercept for Neovascular Age

  • 125418Orig1s000

    125418Orig1s000

  • Osteonecrosis of the Jaw Associated with Ziv-Aflibercept

    Osteonecrosis of the Jaw Associated with Ziv-Aflibercept

  • Protocol T Year 2: What Doctors Are Saying

    Protocol T Year 2: What Doctors Are Saying

  • Osteonecrosis of Jaw Beyond Antiresorptive (Bone-Targeted)

    Osteonecrosis of Jaw Beyond Antiresorptive (Bone-Targeted)

  • CDER List of Licensed Biological Products With

    CDER List of Licensed Biological Products With

  • Brentuximab Vedotin Related Bilateral Purtscher-Like Retinopathy Unresponsive to Pulse Steroid Therapy and Intravitreal Aflibercept Injection

    Brentuximab Vedotin Related Bilateral Purtscher-Like Retinopathy Unresponsive to Pulse Steroid Therapy and Intravitreal Aflibercept Injection

  • Oncology Dose Reduction Program Beginning July 1, 2021

    Oncology Dose Reduction Program Beginning July 1, 2021

  • Comparison of Vascular Endothelial Growth Factor Inhibitors on Macular Oedema Secondary Central Retinal Vein Occlusion

    Comparison of Vascular Endothelial Growth Factor Inhibitors on Macular Oedema Secondary Central Retinal Vein Occlusion

  • Aflibercept, Ziv-Aflibercept, and Conbercept

    Aflibercept, Ziv-Aflibercept, and Conbercept

  • Stembook 2018.Pdf

    Stembook 2018.Pdf

  • Eylea, INN-Aflibercept

    Eylea, INN-Aflibercept

  • Pharmaceutical Compounding of Aflibercept in Prefilled Syringes

    Pharmaceutical Compounding of Aflibercept in Prefilled Syringes

Top View
  • Silverback Care Management CARE N' CARE Specialty Drug
  • Emerging Therapies in the Management Of
  • EYLEA • Ocular Or Periocular Infection (4.1) Safely and Effectively
  • Treatment with Brentuximab Vedotin Prior to Reduced Intensity Allogeneic HCT in Relapsed/ Refractory HL
  • 2017 Annual Report
  • Structural Basis for Vascular Endothelial Growth Factor Receptor Activation and Implications for Disease Therapy
  • Clinical Policy: Aflibercept (Eylea)
  • Most Favored Nation
  • Multi-Indication Pricing: Pros, Cons and Applicability to the UK
  • Aflibercept – How Does It Compare with Other Anti-VEGF Drugs?
  • Specialty Injectables Prior Authorization List
  • Randomized Trial of Intravitreous Aflibercept Versus Intravitreous Bevacizumab + Deferred Aflibercept for Treatment of Central-Involved Diabetic Macular Edema
  • Commissioned List of Indications 2021-2022
  • Regeneron Pharmaceuticals, Inc
  • Corporate Fact Sheet
  • Temsirolimus Inhibits Proliferation and Migration in Retinal Pigment Epithelial and Endothelial Cells Via Mtor Inhibition and Decreases VEGF and PDGF Expression
  • GUIDELINE for MANAGEMENT of EXTRAVASATION Extravasation Is a Severe Complication in the Administration of Cytotoxic Chemotherapy
  • TRANSPARENCY COMMITTEE Opinion 3 April 2013


© 2024 Docslib.org    Feedback